Tecvayli (teclistamab-cqyv) — Medica
Multiple myeloma, relapsed or refractory
Initial criteria
- age ≥ 18 years
- patient has tried at least four systemic regimens
- among the previous regimens, patient has received at least one drug from each of the following classes: proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody
- prescribed by or in consultation with an oncologist
Approval duration
1 year